What question did this study set out to answer?

To assess the efficacy of sentinel lymph node biopsy (SLNB) in patients with clinically node-negative Merkel cell carcinoma (MCC).

April 19, 2026ANZ Journal of Surgery2 citationsOpen Access

View Full Paper

Sentinel Lymph Node Biopsy in Clinically Node‐Negative Merkel Cell Carcinoma: An Update of the Westmead Hospital Experience

JAJulie Ahn JHJulie R. HowleThe University of Sydney MVMichael J. Veness

Key Points

To assess the efficacy of sentinel lymph node biopsy (SLNB) in patients with clinically node-negative Merkel cell carcinoma (MCC).
Analyzed data from patients with clinically node-negative MCC
Evaluated SLNB positivity rates
Assessed false-negative rates under close surveillance
SLNB positivity rate of nearly 40%
Supports improved staging accuracy in MCC management
Demonstrates acceptable false-negative rates

Abstract

MCC demonstrates a high rate of subclinical nodal metastases, with a SLNB positivity rate of nearly 40% in our series. These findings support the use of SLNB in the management of clinically node-negative MCC to improve staging accuracy, prognostication and guide management decisions, with an acceptable false-negative rate under close surveillance.

اسأل الذكاء الاصطناعي

Bookmark

View Full Paper

Cite This Study

Ahn et al. (Thu,) studied this question.

synapsesocial.com/papers/69e472d8010ef96374d8ec78 https://doi.org/https://doi.org/10.1111/ans.70692

اسأل الذكاء الاصطناعي

Bookmark

View Full Paper